QPOR Platform for Immunotherapy Response

About 4D Path

4D Path is a private, pre-revenue diagnostics company founded in 2017 and headquartered in Cambridge, Massachusetts. The company has developed the QPOR™ Platform, a proprietary AI/ML platform that extracts novel biological signatures from standard pathology slides to predict therapeutic response across multiple cancer types and drug classes. With FDA Breakthrough Device Designation for breast cancer diagnostics and validation studies with leading cancer centers, 4D Path is positioning its technology as a tool for both clinical decision support and biopharma drug development partnerships.

Therapeutic Areas